Portfolio

 

Proprietary Pipeline

Preclinical phase
Clinical phase
 
Project, Mechanism
 
Disease area
 
Preclinical
 
Phase I
 
Phase II
 
Phase III
 
Market
Remetinostat
Topical HDAC inhibitor
Cutaneous T-cell lymphoma
Birinapant
SMAC mimetic
Solid tumors, combo with Keytruda™
MIV-818
Nucleotide DNA polymerase inhibitor
Hepatocellular carcinoma
MIV-711
Cathepsin K inhibitor
Osteoarthritis

 

Partnership Pipeline

Preclinical phase
Clinical phase
 
Project
 
Disease area
 
Partner
 
Preclinical
 
Phase I
 
Phase II
 
Phase III
 
Market
Xerclear Labial herpes GSK and Meda
MIV-802
Nucleotide NS5B polymerase inhibitor
Hepatitis C Ascletis (Greater China) Trek Therapeutics (rest of world)

 

Page updated 16 February 2018